Cargando…

Economic Burden Associated with Receiving Inhaled Corticosteroids with Leukotriene Receptor Antagonists or Long-Acting Beta Agonists as Combination Therapy in Older Adults

BACKGROUND: There is a paucity of literature on the health care expenditures associated with different pharmacologic treatments in older adults with asthma that is not well controlled on inhaled corticosteroids (ICS). OBJECTIVE: To compare asthma-related and all-cause health care expenditures associ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Altawalbeh, Shoroq M., Thorpe, Carolyn T., Zgibor, Janice C., Kane-Gill, Sandra, Kang, Yihuang, Thorpe, Joshua M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7977940/ https://www.ncbi.nlm.nih.gov/pubmed/29694289 http://dx.doi.org/10.18553/jmcp.2018.24.5.478

Ejemplares similares

Comparison of pneumonia incidence between long-acting muscarinic antagonist and inhaled corticosteroid plus long-acting beta agonist in patients with COPD
por: Lee, Eung Gu, et al.
Publicado: (2023)

Prescribing of long-acting beta-2-agonists/inhaled corticosteroids after the SMART trial
por: Rottenkolber, Marietta, et al.
Publicado: (2015)

Add-on Therapy for Symptomatic Asthma despite Long-Acting Beta-Agonists/Inhaled Corticosteroid
por: Dreher, Michael, et al.
Publicado: (2018)

Effect of Adding Inhaled Corticosteroid to Long-Acting Muscarinic Antagonist/Long-Acting Beta-Agonist Therapy Among Patients With Chronic Obstructive Pulmonary Disease
por: Yuasa, Mizuki, et al.
Publicado: (2021)

Estimating Inhaled Corticosteroid Exposure from Short-Acting β(2)-Agonist–Inhaled Corticosteroid Rescue
por: Lugogo, Njira, et al.
Publicado: (2023)

Targeting the Small Airways with Inhaled Corticosteroid/Long-Acting Beta Agonist Dry Powder Inhalers: A Functional Respiratory Imaging Study
por: Watz, Henrik, et al.
Publicado: (2021)

RETRACTED ARTICLE: Inhaled corticosteroids and long-acting beta-agonists in adult asthma: a winning combination in all?
por: Postma, Dirkje S., et al.
Publicado: (2008)

Retraction Note to: Inhaled corticosteroids and long-acting beta-agonists in adult asthma: a winning combination in all?
por: Postma, Dirkje S., et al.
Publicado: (2009)

The benefits of combined treatment with corticosteroids and long-acting beta agonists
por: Singh, Dave
Publicado: (2006)

Severe exacerbation and pneumonia in COPD patients treated with fixed combinations of inhaled corticosteroid and long-acting beta2 agonist
por: Yang, Hsi-Hsing, et al.
Publicado: (2017)

Risk of sepsis among patients with COPD treated with fixed combinations of inhaled corticosteroids and long-acting Beta2 agonists
por: Wang, Cheng-Yi, et al.
Publicado: (2019)

Real-Life Patterns of Exacerbations While on Inhaled Corticosteroids and Long-Acting Beta Agonists for Asthma over 15 Years
por: McGeachie, Michael J., et al.
Publicado: (2020)

Asthma control in patients receiving inhaled corticosteroid and long-acting beta(2)-agonist fixed combinations. A real-life study comparing dry powder inhalers and a pressurized metered dose inhaler extrafine formulation
por: Müller, Veronika, et al.
Publicado: (2011)

Applying the Risk of Bias Tool in a Systematic Review of Combination Long-Acting Beta-Agonists and Inhaled Corticosteroids for Persistent Asthma
por: Hartling, Lisa, et al.
Publicado: (2011)

Long-acting beta-agonists plus inhaled corticosteroids safety: a systematic review and meta-analysis of non-randomized studies
por: Hernández, Gimena, et al.
Publicado: (2014)

Impact of extrafine formulations of inhaled corticosteroids/long-acting beta-2 agonist combinations on patient-related outcomes in asthma and COPD
por: Scichilone, Nicola, et al.
Publicado: (2014)

Risk of active tuberculosis among COPD patients treated with fixed combinations of long-acting beta2 agonists and inhaled corticosteroids
por: Huang, Tsan-Ming, et al.
Publicado: (2020)

Medication Cost-Savings and Utilization of Generic Inhaled Corticosteroid (ICS) and Long-Acting Beta-Agonist (LABA) Drug Products in the USA
por: Wang, Zhong, et al.
Publicado: (2022)

Asthma diagnosis and treatment – 1018. Effect of inhaled corticosteroids with long-acting beta2 agonists vs. inhaled corticosteroids alone on asthma control in children: results from national ashtma survey
por: Lockey, Richard F, et al.
Publicado: (2013)

Blood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPD
por: Pavord, Ian D, et al.
Publicado: (2016)

Leukotriene Antagonists in Dermatology
por: Bubna, Aditya Kumar
Publicado: (2021)

Prescription Patterns of New Use of Fixed-Dose Combination Inhalers in Patients with Chronic Obstructive Pulmonary Disease: Long-Acting β2 Agonists Plus Long-Acting Muscarinic Antagonists versus Long-Acting β2 Agonists Plus Inhaled Corticosteroids
por: Liao, Pei-An, et al.
Publicado: (2023)

Comparative efficacy of inhaled corticosteroid and long-acting beta agonist combinations in preventing COPD exacerbations: a Bayesian network meta-analysis
por: Oba, Yuji, et al.
Publicado: (2014)

Effects of two inhaled corticosteroid/long-acting beta-agonist combinations on small-airway dysfunction in mild asthmatics measured by impulse oscillometry
por: Diong, Bill, et al.
Publicado: (2013)

Association between ADAM33 Single-Nucleotide Polymorphisms and Treatment Response to Inhaled Corticosteroids and a Long-Acting Beta-Agonist in Asthma
por: Vishweswaraiah, Sangeetha, et al.
Publicado: (2023)

An assessment of asthma exacerbations in pediatric patients using a long-acting B2-agonist plus inhaled corticosteroid versus an inhaled corticosteroid alone
por: Alakeel, Yousif S., et al.
Publicado: (2022)

Efficacy and safety of the CRTh2 antagonist AZD1981 as add-on therapy to inhaled corticosteroids and long-acting β(2)-agonists in patients with atopic asthma
por: Bateman, Eric D, et al.
Publicado: (2018)

Cardiovascular outcomes with an inhaled beta2-agonist/corticosteroid in patients with COPD at high cardiovascular risk
por: Brook, Robert D, et al.
Publicado: (2017)

Comparison of vilanterol, a novel long-acting beta(2) agonist, with placebo and a salmeterol reference arm in asthma uncontrolled by inhaled corticosteroids
por: Lötvall, Jan, et al.
Publicado: (2014)

The association between seasonal asthma exacerbations and viral respiratory infections in a pediatric population receiving inhaled corticosteroid therapy with or without long-acting beta-adrenoceptor agonist: A randomized study()
por: Prazma, Charlene M., et al.
Publicado: (2015)

A comparison of tiotropium, long-acting β(2)-agonists and leukotriene receptor antagonists on lung function and exacerbations in paediatric patients with asthma
por: Vogelberg, Christian, et al.
Publicado: (2020)

Low adherence to inhaled corticosteroids/long-acting β(2)-agonists and biologic treatment in severe asthmatics
por: Caminati, Marco, et al.
Publicado: (2020)

Impact of adherence to treatment with inhaled corticosteroids/long-acting β-agonists on asthma outcomes in the United States
por: Averell, Carlyne M., et al.
Publicado: (2022)

Lung function decline before and after treatment of World Trade Center associated obstructive airways disease with inhaled corticosteroids and long‐acting beta agonists
por: Goldfarb, David G., et al.
Publicado: (2021)

Efficacy and safety of single-inhaler extrafine triple therapy versus inhaled corticosteroid plus long-acting beta2 agonist in eastern Asian patients with COPD: the TRIVERSYTI randomised controlled trial
por: Zheng, Jinping, et al.
Publicado: (2021)

Transcriptome analysis in patients with asthma after inhaled combination therapy with long-acting β2-agonists and corticosteroids
por: Liang, Ya-Ru, et al.
Publicado: (2022)

Neuropsychiatric side reactions of leukotriene receptor antagonist, antihistamine, and inhaled corticosteroid: A real-world analysis of the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS)()
por: Bian, Sainan, et al.
Publicado: (2021)

Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β(2)-agonist fixed-dose combination: RE(2)SPOND rationale and study design
por: Rennard, Stephen I, et al.
Publicado: (2016)

A smarter way to manage asthma with a combination of a long-acting β(2)-agonist and inhaled corticosteroid
por: Selroos, Olof
Publicado: (2007)

Inhaled Corticosteroids and Bone Health
por: Chee, Carolyn, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_k46735rdjj30hv02jug5vpuntc